Home » Authors » James Etheridge

Articles by James Etheridge

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Aug. 9, 2006

By James Etheridge

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Aug. 9, 2006

By James Etheridge

NicOx To Initiate Two Phase II Trials Of NCX 4016 In Diabetes

Aug. 2, 2006

By James Etheridge

NicOx To Initiate Two Phase II Trials Of NCX 4016 In Diabetes

Aug. 2, 2006

By James Etheridge

Cellectis, Lexicon Genetics Exchange Rights To Patents

July 19, 2006

By James Etheridge

Cellectis, Lexicon Genetics Exchange Rights To Patents

July 19, 2006

By James Etheridge

LTKfarma Setting Up Shop With Product In Phase I/II

July 12, 2006

By James Etheridge

Eurofins Scientific Invests In Danish, Japanese Food Firms

July 12, 2006

By James Etheridge

Eurofins Scientific Invests In Danish, Japanese Food Firms

July 12, 2006

By James Etheridge

LTKfarma Setting Up Shop With Product In Phase I/II

July 12, 2006

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...